Report Highlights

U.S. Position in the Global Digital Therapeutics Supply Chain

The United States anchors digital therapeutics as a software-led design and licensing hub rather than a volume manufacturer. Boston, San Francisco and the Research Triangle host the clinical validation, FDA submission and software engineering that global licensees depend on for market access. Hardware components for sensor-linked programs, including Bluetooth chipsets and inertial sensors, are imported largely from China, Taiwan, Vietnam and Malaysia. Customs records show hardware inflows far exceed outbound device shipments, leaving services and IP licensing as the only consistent net positive.

Domestic demand absorbs most platform output, so trade exposure concentrates in inputs and reimbursement-linked hardware. Cloud hosting relies on AWS, Microsoft Azure and Google Cloud regions in Virginia, Oregon and Iowa, creating data residency obligations under HIPAA. The strategic vulnerability lies in semiconductor concentration, since a single Taiwan Strait disruption would halt sensor production for several connected therapies. Vietnamese contract manufacturing has expanded to offset China exposure, though yields remain lower.

Growth Drivers Behind U.S. Digital Therapeutics Production

Medicare's 2025 creation of HCPCS codes G0552 through G0554 for digital mental health treatment devices has converted pilot programs into billable services. Manufacturers are responding by expanding U.S. software engineering teams and contracting domestic cloud capacity, shifting spend away from one-off device sales toward recurring subscription revenue. Otsuka's Rejoyn, cleared by FDA in 2024 as a prescription digital therapeutic for depression, shows pharma-backed programs entering the supply chain.

Employer-sponsored benefits form the second growth driver, as self-insured firms seek musculoskeletal and diabetes programs that reduce claims costs. Omada Health and Hinge Health are scaling production of connected kits through Asian contract assemblers. Akili's EndeavorRx prescription game, cleared in 2020, was acquired by Virtual Therapeutics in 2024, signalling consolidation. Import substitution is emerging for sensor modules as domestic assembly partnerships develop alongside Texas and Arizona semiconductor clusters.

Supply Chain Risks and Trade Barriers for U.S. Digital Therapeutics

Section 301 tariffs on Chinese semiconductors and electronics raise landed costs for sensor-based therapeutics, and escalation since 2018 has pushed many buyers to route production through Vietnam and Malaysia. Transshipment scrutiny by U.S. Customs and Border Protection adds documentation risk for companies with mixed-origin bills of materials. Mexican assembly offers proximity but limited component depth for sensor electronics.

FDA's evolving Software as a Medical Device framework creates regulatory timing risk, as predetermined change control plans are still being standardised. Data residency requirements under HIPAA and state privacy laws, including California's CCPA, complicate cross-border cloud hosting. Currency exposure is limited because most revenue is dollar-denominated, but European licensing income carries euro translation risk.

Trade and Investment Opportunities in U.S. Digital Therapeutics

Export opportunities centre on licensing digital therapeutic intellectual property and clinical evidence packages to European and Japanese partners facing slower reimbursement pathways. Germany's DiGA system and Japan's PMDA pathways allow sponsors to build dossiers that draw on U.S.-generated trial evidence. Licensing deals with European payers and manufacturers offer American developers a capital-light channel into markets that lack domestic software engineering depth.

Inbound foreign direct investment into domestic sensor assembly and cloud infrastructure offers the clearest capacity opportunity. Texas and Arizona semiconductor expansions, supported by CHIPS and Science Act manufacturing incentives, make these states viable sites for medical-grade wearable assembly. Logistics hubs in Memphis and Louisville, home to major express carrier networks, can serve as distribution points for connected kit fulfilment.

Regulatory and Trade Policy Environment for U.S. Digital Therapeutics

FDA regulates most digital therapeutics as Class II or De Novo medical devices under the Federal Food, Drug, and Cosmetic Act, with the Digital Health Center of Excellence overseeing review. CMS reimbursement runs through the Physician Fee Schedule, while the Harmonized Tariff Schedule determines duty classification for imported devices. Section 232 and Section 301 measures apply to electronics content, so component classification directly affects landed cost.

Investment policy is shaped by CFIUS review of foreign acquisitions of U.S. health data companies and by the Protecting Americans' Data from Foreign Adversaries Act of 2024, which restricts transfers of sensitive health data to designated countries. Companies with Chinese ownership face divestiture pressure. Federal R&D tax credits and state economic development grants offer incentives for domestic production capacity.

U.S. Digital Therapeutics Supply Chain Outlook to 2032

Hardware dependence will decline as software-only therapeutics gain share, reducing tariff exposure across the category by 2032. Prescription digital therapeutics for psychiatric conditions are shifting production toward cloud-delivered software, which cuts component imports and shortens manufacturing lead times. Sensor-enabled products will remain concentrated in cardiometabolic and musculoskeletal programs where continuous data collection justifies hardware costs.

Domestic sensor assembly capacity in Texas and Arizona will reduce China-origin content as CHIPS-funded fabrication comes online, though medical-grade qualification will keep Asian contract manufacturers central through the decade. Payer-led reimbursement, rather than device volume, will determine which platforms scale. Consolidation among mid-tier vendors will accelerate as capital requirements for compliance and payer contracting rise.

Market at a Glance

Leading Market Participants

• Otsuka Pharmaceutical
• Click Therapeutics
• Omada Health
• Hinge Health
• Akili Interactive
• DarioHealth
• Freespira
• Big Health
• Welldoc
• Biofourmis